Chris Dwyer

Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial

John Foley, Gilles Defer, Lana Zhovtis Ryerson et al. · The Lancet Neurology · 2022 · 103 citations

Relapsing-remitting Multiple Sclerosis, Clinical Neurology, Clinical Trials +8

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

Nabil Seery, Sifat Sharmin, Vivien Li et al. · CNS Drugs · 2021 · 41 citations · Full text

Retrospective Cohort Study, Autoimmune Disease, Disease Progression +9

The role of venous sinus outflow obstruction in pediatric idiopathic intracranial hypertension

Chris Dwyer, Kristina Prelog, Brian Owler · Journal of Neurosurgery Pediatrics · 2012 · 34 citations

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Chris Dwyer, Vilija Jokubaitis, Jim Stankovich et al. · Therapeutic Advances in Neurological Disorders · 2021 · 14 citations · Full text

Neutropaenia complications from Ocrelizumab and Rituximab treatment

Venus Pang, Nabil Seery, Robb Wesselingh et al. · Multiple Sclerosis and Related Disorders · 2023 · 13 citations · Full text